本报讯(记者袁传玺) 日前，礼来制药旗下穆峰达(替尔泊肽注射液多剂量预装笔)在京东健康股份有限公司(以下简称"京东健 康")线上首发。穆峰达作为全球首个且目前唯一获批用于2型糖尿病和长期体重管理的GIP/GLP-1受体激 动剂，自上市以来便以其独特的双重作用机制和显著的疗效，赢得了广大患者的信赖与好评。此次替尔 泊肽注射液多剂量预装笔，是礼来制药推出的新型注射装置，将为患者带来全新的选择。 京东健康相关负责人表示："我们非常高兴能够与礼来制药合作，率先引入穆峰达多剂量预装笔。这款 改进剂型将在京东买药秒送独家首发，并同步在京东买药上线，给患者带来更加方便、快捷的购买体 验。未来，我们将继续与全球药企紧密合作，共同推动新特药的普及和可及性，为更多患者提供精准、 高效的治疗方案。" 随着穆峰达多剂量预装笔在京东健康平台的线上首发，相信将有更多2型糖尿病和肥胖患者从中受益， 实现更加健康、美好的生活。 此次，礼来制药改进了穆峰达的注射装置。穆峰达(替尔泊肽注射液多剂量预装笔)采用了创新的"4剂集 成"设计，每支笔包含四个固定剂量，每周使用一个剂量，即可满足患者一个月的治疗需求。这一设计 不仅简化了用药流程，减少了患 ...

Group 1 - The core viewpoint of the article highlights the launch of Eli Lilly's Mounjaro® (tirzepatide injection multi-dose prefilled pen) on JD Health, marking it as the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management [1][2] - Mounjaro® features an innovative "4-dose integration" design, allowing patients to use one fixed dose per week, thus simplifying the medication process and improving adherence [1] - The multi-dose prefilled pen can be stored at room temperature not exceeding 30°C for 30 days after the first use, enhancing convenience for patients during travel or daily use [1] Group 2 - The user experience of Mounjaro® multi-dose prefilled pen is emphasized, with simple operation steps and a fine needle that reduces pain during injection, improving patient comfort [2] - JD Health expresses excitement about collaborating with Eli Lilly to exclusively launch Mounjaro® on their platform, aiming to enhance accessibility and convenience for patients [2] - The launch of Mounjaro® is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2]

Core Insights - The implementation of the "Childcare Subsidy System" by the Chinese government aims to reduce family childbirth costs and boost the maternal and infant consumption market [1] - The shift in purchasing behavior among young parents from "basic prevention" to "scientific parenting" is driving significant market growth [1] - The domestic maternal and infant nutrition market is projected to reach 130 billion yuan by 2025, with increasing demand for scientifically formulated products [1] Group 1: Market Trends - Young parents are becoming more selective in their parenting choices, leading to a demand for products that cater to specific nutritional needs during different stages of pregnancy and childcare [1][2] - The market is experiencing rapid growth in niche categories such as DHA and probiotics, driven by the trend towards refined parenting [1][2] Group 2: Company Strategies - PERDAYS, an Australian brand, focuses on "staged nutrition" tailored to different phases of pregnancy and motherhood, addressing specific consumer pain points [2][4] - The brand has successfully launched products like active folic acid tablets and sugar-free iron supplements, which cater to the unique needs of pregnant women [2][4] Group 3: Marketing and Collaboration - PERDAYS collaborates with JD Health to enhance its marketing strategy, utilizing targeted advertising and promotional activities to increase product visibility and sales [4][5] - The partnership has resulted in significant sales growth, with some products achieving a fourfold increase in transaction value [4][6] Group 4: Industry Position - JD Health has established itself as a leading online sales channel for maternal and infant nutrition products, achieving the highest market share in the second quarter of 2025 [5][6] - The collaboration between PERDAYS and JD Health exemplifies how deep consumer insights and precise marketing can redefine the value of scientific parenting [6]

Core Points - JD Health (06618.HK) announced that it will hold a board meeting on August 14, 2025, to approve the unaudited interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 董事會會議日期 京东健康股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於 2025年8月14日（星期四）舉行董事會會議，以（其中包括）批准本公司及其子公司截至2025 年6月30日止六個月之未經審計中期業績及其發佈，以及考慮建議派付中期股息（如有）。 本公司管理層將於2025年8月14日（星期四）下午七時正（北京╱香港時間）舉行電話會議， 以討論本公司及其子公司截至2025年6月30日止六個月的中期業績。 有意參加電話會議的參與者請在電話會議計劃開始時間前至少10分鐘進行撥入，並按照 提示輸入參會者密碼以進入電話會議。 撥入號碼： 普通話頻道參會者密碼：452174 英文頻道參會者密碼： 182612 ...

Core Insights - The article highlights the launch of a new oral Bcl-2 selective inhibitor, Lisangtuo® (generic name: Lishatoklaku), developed by Ascentage Pharma, which is now exclusively available on JD Health [1][3] - Lisangtuo® is the first domestically approved original Bcl-2 inhibitor in China and the second globally, aimed at treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have undergone at least one prior systemic therapy including BTK inhibitors [1][3] - The drug works by selectively inhibiting the Bcl-2 protein, restoring normal apoptosis in tumor cells, and is expected to have fewer interactions with common drugs and more controllable effects on platelets compared to traditional CLL/SLL medications [1][3] Industry Context - The development of Bcl-2 inhibitors is challenging due to complex protein-protein interactions and the need for the drug to penetrate both the cell membrane and mitochondrial membranes [3] - Prior to Lisangtuo®, no Bcl-2 inhibitors had been approved for CLL/SLL treatment in China, indicating a significant advancement in the field [3] - The successful launch of Lisangtuo® represents a major step for China in the treatment of hematological malignancies and showcases Ascentage Pharma's leading capabilities in global innovative research and development [3] Distribution Strategy - JD Health is leveraging its capabilities in pharmaceutical supply chain and healthcare services to provide comprehensive support, including drug consultation, doctor consultations, and efficient delivery for users in need [4]

Core Viewpoint - The article highlights the significant role of JD Health in promoting liver health awareness and improving liver disease prevention and treatment through its digital healthcare services and pharmaceutical supply chain advantages [2][3][4]. Group 1: Industry Context - The number of liver disease patients in China is substantial, including carriers of viral hepatitis (HBV/HCV), long-term alcohol consumers, individuals with metabolic syndrome, and drug abusers [2]. - The liver performs over 500 essential physiological functions daily, and its health directly impacts overall quality of life [2]. Group 2: Company Initiatives - JD Health hosted the "Scientific Liver Protection, Healthy Future" industry forum to showcase its efforts in liver disease management and support for pharmaceutical companies [2]. - JD Health has established a comprehensive digital service system covering the entire liver disease management cycle, leveraging its pharmaceutical supply chain and digital capabilities [3]. - The company reported a more than 40% year-on-year increase in sales of antiviral and liver-protecting traditional Chinese medicine in the past year, particularly in lower-tier markets [3]. Group 3: Consumer Trends - A report released by JD Health and Zhongkang Technology indicates a growing trend in liver health product consumption, with a projected 26% year-on-year growth in 2024 [4]. - Patients are spending an average of over 1,800 yuan annually on liver health products, with a high repurchase rate exceeding 50% and an average of nearly 7 purchases per year [4]. Group 4: Future Directions - JD Health is forming a "Scientific Liver Protection" alliance with various pharmaceutical companies to enhance public awareness of liver diseases and promote standardized health education [5]. - The company aims to build a more comprehensive disease prevention and patient service system, focusing on early screening and treatment of liver diseases [5].

Core Insights - The 2025 World Artificial Intelligence Conference (WAIC) was held in Shanghai, where JD Health showcased its latest AI achievements, particularly the advancements of the "Jingyi Qianxun" medical model and its future directions [1][4] - JD Health's medical AI solutions were included in the "2025 Sustainable Innovation Case Recommendations" list, highlighting its industry-leading position in medical model technology innovation and AI application [1][5] Group 1: JD Health's AI Model Developments - JD Health's self-developed medical model "Jingyi Qianxun" has been continuously upgraded to version 2.0 since its full open-source release in February, focusing on expanding AI applications from general services to more complex specialized fields [2] - The "Jingyi Qianxun 2.0" model features a "three engines + four models" architecture, which includes evidence-based data, clinical case engines, and patient-doctor interaction simulation engines, aimed at enhancing the capabilities of its four models [2][3] Group 2: Technological Breakthroughs - Significant breakthroughs have been achieved in "human-like dialogue," "trustworthy reasoning," and "medical multimodality," enhancing user experience and ensuring reliable medical reasoning through extensive clinical evaluations [3] - The model's ability to analyze multimodal medical data, including text, images, and test results, supports precise diagnosis and treatment [3] Group 3: Industry Recognition and Impact - The "2025 Sustainable Innovation Case Recommendations" were established to recognize AI's deep application in healthcare, addressing critical issues like accessibility and affordability of medical services [5][6] - JD Health has launched several AI medical products, including "AI Jingyi," "JD Zhuoyi," and "Kangkang," covering various healthcare scenarios from online consultations to health management [6] Group 4: Product Expansion and User Engagement - JD Health's internet hospital has launched over 500 expert doctor AI agents, making it the largest platform in terms of the number of AI agents and service scale in the industry [9] - The AI doctor "Daiwei" has significantly improved its capabilities, serving over one million users within a month and achieving a service satisfaction rate exceeding 97% [9] Group 5: Future Directions - JD Health aims to deepen its focus on medical AI, enhancing the value of large models in more scenarios to provide high-quality, efficient, and professional healthcare services to a broader audience [10]

Group 1 - The core viewpoint of the article highlights the growing market for liver health products, driven by high customer spending and frequent repurchases, with a projected sales growth of 26% in 2024 for liver health medications [1] - The average annual expenditure for patients on liver health products exceeds 1800 yuan, with an average transaction value of over 260 yuan and a repurchase rate exceeding 50%, indicating a strong consumer commitment [1] - The number of online consultations for liver disease is increasing significantly, with a growth rate of over 67% from Q2 2024 to Q2 2025 [1] Group 2 - Experts emphasize the importance of raising public awareness about liver health and promoting early screening and treatment as key strategies in liver disease prevention [2] - Pharmaceutical companies are committed to increasing R&D investments in liver disease prevention and treatment, with innovative therapies being developed, such as the "dual-antibody therapy" targeting liver fibrosis [2] - Internet medical platforms are seen as crucial in addressing patient pain points by integrating screening, diagnosis, standardized treatment, and management [2] Group 3 - JD Health's sales of antiviral drugs and liver health traditional Chinese medicine have seen over 40% year-on-year growth, particularly in lower-tier markets [3] - JD Health has expanded its home testing services for liver function and hepatitis B screening, now covering 23 cities nationwide, enhancing accessibility for patients [3]

Group 1 - The 2025 World Artificial Intelligence Conference (WAIC) held in Shanghai featured the "AI + Healthcare Industry Sustainable Innovation Forum," where the "2025 Healthcare Sustainable Innovation Case Recommendation List" was released, highlighting the importance of technology in promoting healthcare accessibility and social value creation [1][3] - JD Health's medical AI model solution was recognized in the recommendation list, showcasing its leading advantages in technological innovation and practical application [1][3] - The recommendation list was initiated by multiple organizations, including Yicai Media and the Shanghai Modern Service Industry Association, aiming to discover and celebrate outstanding cases that promote sustainable innovation in the healthcare sector [3] Group 2 - The AI Sustainable Innovation Case Nomination Committee emphasized that accelerating the deep application of AI is crucial for addressing the public's pain points regarding healthcare accessibility and affordability [3] - JD Health has launched the first fully open-source vertical model in the domestic medical industry, "Jingyi Qianxun," along with a series of AI medical products such as "AI Jingyi," "JD Zhuoyi," and "Kangkang," covering various healthcare scenarios [3][5] - "AI Jingyi" has served over 50 million users in just six months and has introduced over 500 intelligent expert doctor agents, establishing a comprehensive AI health service matrix [3][5] Group 3 - At the WAIC 2025 exhibition area, JD Health showcased its AI medical products, generating significant interest and interaction among attendees [5] - JD Health's Chief Scientist, Wang Guoxin, stated that since the full open-source launch in February, the company has focused on developing "Jingyi Qianxun 2.0" to advance AI in healthcare from general services to more complex specialized fields [5]